NextFin News - A subsidiary of McKesson Corp. has priced a $2.25 billion leveraged loan, marking a critical step in the healthcare giant’s multi-year strategy to spin off its Medical-Surgical business. The financing, finalized on Wednesday, June 3, 2026, establishes the independent capital structure necessary for the unit to operate as a standalone entity ahead of its anticipated initial public offering.
The $2.25 billion term loan was priced at a spread of 200 basis points over the Secured Overnight Financing Rate (SOFR), according to Bloomberg. This pricing reflects a robust appetite in the leveraged finance market for healthcare credits, even as broader macroeconomic volatility persists. The proceeds are earmarked to fund a dividend to the parent company and to provide the new entity with initial working capital. McKesson, which reported full-year fiscal 2026 sales of $403.43 billion, has been methodically untangling the Medical-Surgical division, a process that included the completion of key transition service agreements earlier this year.
The move follows a broader trend of corporate "de-cluttering" as U.S. President Trump’s administration maintains a regulatory environment that, while generally pro-business, has scrutinized large-scale healthcare mergers. By spinning off the Medical-Surgical unit—which provides logistics and supply distribution across alternate care settings—McKesson aims to sharpen its focus on high-margin specialty and oncology services. Brian Tyler, CEO of McKesson, previously indicated that the business is on track for an IPO in the second half of 2027, though the pricing of this loan suggests the foundational financial architecture is being laid well in advance.
Market analysts remain divided on the timing of the spin-off. Kevin Kingsbury (Bloomberg) has noted that the successful pricing of such a large loan in the current environment demonstrates institutional confidence in the unit’s cash-flow stability. Kingsbury, a veteran credit market reporter known for a data-centric and cautious approach to corporate debt cycles, suggests that the 200-basis-point spread is a "win" for McKesson, placing the debt at the tighter end of recent healthcare issuances. However, this perspective is not yet a universal consensus. Some sell-side analysts at firms like Barclays have cautioned that the Medical-Surgical business faces headwinds, with revenue growth expected to sit at the lower end of its 2% to 6% target range due to fluctuating illness trends and regulatory pressure on pharmaceutical margins.
The leveraged loan market itself is navigating a complex period. While the first quarter of 2026 saw a rotation toward fresh M&A and LBO issuance, the recent U.S.-Iran military tensions and an AI-driven reassessment of credit quality in the tech sector have made investors more selective. In this context, McKesson’s ability to secure $2.25 billion at competitive rates highlights the "flight to quality" currently dominating the credit markets. Investors are favoring established, cash-generative healthcare businesses over more speculative growth plays.
The risk for the upcoming IPO lies in the execution of the separation. While the loan provides the necessary liquidity, the Medical-Surgical unit must now prove it can maintain its 2031 maturity profile and manage its new debt load without the safety net of the parent company’s massive balance sheet. If pharmaceutical margin compression accelerates or if the IPO market cools significantly by 2027, the unit may find itself burdened by the very leverage that facilitated its independence.
Explore more exclusive insights at nextfin.ai.
